Snapshot from Jul 27, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Iswarya Fertility raises $37M from OrbiMed
Business growth investment

Iswarya Fertility raises $37M from OrbiMed

Analysis based on 7 articles · First reported Jul 09, 2026 · Last updated Jul 10, 2026

Sentiment
20
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The investment signals strong investor confidence in India's fertility care market, which is poised for growth due to declining fertility rates and rising demand. OrbiMed's backing may boost Iswarya's expansion and market position, potentially increasing competition in the sector.

Healthcare Fertility Services
Event Summary

Chennai-based Iswarya Fertility Center has raised over ₹350 crore (approximately $37 million) in a growth investment from OrbiMed, a global healthcare investment firm. The funding will be used to establish new centers in existing and underserved markets, strengthen clinical infrastructure, invest in digital capabilities, and expand its embryology talent pipeline. Iswarya, founded in 1986, operates more than 85 centers across eight states in India and has served over 300,000 couples. The investment marks Iswarya's maiden external funding round and is one of the largest growth investments in India's IVF sector. India's total fertility rate has fallen to 1.9, below the replacement rate, driving demand for fertility services. The IVF market in India is expected to grow at a CAGR of 14-18% and exceed $4 billion by 2030. Veda Corporate Advisors acted as financial adviser to Iswarya.

Key Actions
100 Iswarya Fertility Center raised growth investment OrbiMed
80 Iswarya Fertility Center plans to expand
20 Veda Corporate Advisors acted as financial adviser Iswarya Fertility Center
Entities Involved
priv
Iswarya Fertility Center
Iswarya received a $37M growth investment from OrbiMed, enabling expansion and strengthening its position as a leading fertility platform in India.
Importance 100.0 Sentiment 80.0
priv
OrbiMed
OrbiMed invested in Iswarya, extending its India portfolio into fertility care, reflecting confidence in the sector's growth.
Importance 80.0 Sentiment 60.0
per
Arun Muthuvel
As managing director, Muthuvel leads Iswarya's expansion strategy and announced the investment.
Importance 60.0 Sentiment 50.0
cnt
India
India's declining fertility rate and growing demand for fertility treatments create a favorable market for Iswarya's expansion.
Importance 50.0 Sentiment 40.0
per
S. Chandralekha
Founder and chief clinical officer, Chandralekha's clinical excellence is central to Iswarya's brand.
Importance 40.0 Sentiment 40.0
per
Sunny Sharma
Partner at OrbiMed, Sharma commented on the partnership, highlighting Iswarya's clinical outcomes.
Importance 30.0 Sentiment 30.0
per
Arun Sadhanandham
Managing director at OrbiMed, Sadhanandham jointly commented on the investment.
Importance 30.0 Sentiment 30.0
priv
Veda Corporate Advisors
Advised Iswarya on the transaction, facilitating the investment.
Importance 20.0 Sentiment 20.0
per
K. Veluswamy
Co-founder of Iswarya, Veluswamy is part of the leadership team.
Importance 20.0 Sentiment 20.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.